Jazz Pharma director sells 6,000 shares at $250

A Jazz Pharmaceuticals director executed a Rule 10b5-1 planned sale and reported additional share dispositions used to satisfy tax obligations from restricted stock unit vesting.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Bruce C. Cozadd reported selling 6,000 Ordinary Shares of JAZZ on September 1, 2026 at $250.13 per share in an open-market or private transaction. On August 31, 2026, he also disposed of 1,219 shares to pay tax liabilities from vesting restricted stock units, including a previously unreported 3,193-share tax withholding from November 3, 2025. The September 1, 2026 sale was executed under a Rule 10b5-1 trading plan adopted on November 26, 2025.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares

Net Sell 3 txns

Insider COZADD BRUCE C

Role Director

Sold 6,000 shs ($1.50M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F3	6,000	$250.13	$1.50M
Tax Withholding	Ordinary Shares F1, F2	10	$244.064	$2K
Tax Withholding	Ordinary Shares F1	1,209	$241.3899	$292K

Holdings After Transaction: Ordinary Shares — 351,875 shares (Direct)

Footnotes (3)

1. F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
2. F2. Includes the November 3, 2025 disposition of 3,193 shares for the withholding of restricted stock units by the Issuer to satisfy FICA taxes arising from the Reporting Person being retirement eligible which was previously inadvertently not reported; not an open market transaction.
3. F3. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Key Figures

Open-market sale shares: 6,000 shares Open-market sale price: $250.13 per share Tax-withholding dispositions: 1,219 shares +2 more

5 metrics

Open-market sale shares 6,000 shares Ordinary Shares sold on September 1, 2026

Open-market sale price $250.13 per share Price for 6,000 Ordinary Shares sold September 1, 2026

Tax-withholding dispositions 1,219 shares Ordinary Shares disposed of on August 31, 2026 to pay tax liabilities

Tax-withholding prices $244.064 and $241.3899 per share Per-share prices for August 31, 2026 tax-withholding dispositions

Previously unreported tax withholding 3,193 shares Disposition on November 3, 2025 to satisfy FICA taxes on RSUs

Key Terms

Rule 10b5-1, restricted stock units, FICA taxes

3 terms

Rule 10b5-1 regulatory

"This transaction was made pursuant to a plan adopted ... in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock units financial

"tax obligations arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FICA taxes financial

"withholding of restricted stock units by the Issuer to satisfy FICA taxes"

FAQ

What insider transactions did JAZZ director Bruce C. Cozadd report?

He reported selling 6,000 Ordinary Shares on September 1, 2026 at $250.13 per share, plus dispositions totaling 1,219 shares on August 31, 2026 to satisfy tax liabilities related to restricted stock unit vesting.

Was the September 1, 2026 JAZZ share sale under a Rule 10b5-1 plan?

Yes. The 6,000-share sale on September 1, 2026 was made pursuant to a Rule 10b5-1 trading plan adopted by Bruce C. Cozadd on November 26, 2025 and occurred automatically, not as a discretionary transaction.

How many JAZZ shares were disposed of for tax withholding on August 31, 2026?

On August 31, 2026, Bruce C. Cozadd reported disposing of 1,219 shares of Jazz Pharmaceuticals Ordinary Shares at prices of $244.064 and $241.3899 per share to satisfy tax obligations arising from the vesting of restricted stock units.

What previously unreported JAZZ share disposition did the filing disclose?

The filing notes a November 3, 2025 disposition of 3,193 shares for withholding of restricted stock units by Jazz Pharmaceuticals to satisfy FICA taxes due to retirement eligibility, which had been inadvertently not reported earlier and was not an open-market transaction.

Is the Form 4 for JAZZ primarily reporting insider buying or selling?

The Form 4 reports net selling/dispositions, including a 6,000-share sale and 1,219 shares disposed of to cover tax liabilities from restricted stock unit vesting, along with disclosure of a prior 3,193-share tax withholding disposition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 05:04 PM Accepted by SEC EDGAR 09/02/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/31/2026		F(1)		10	D	$244.064	359,084(2)	D
Ordinary Shares	08/31/2026		F(1)		1,209	D	$241.3899	357,875	D
Ordinary Shares	09/01/2026		S(3)		6,000	D	$250.13	351,875	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

2. Includes the November 3, 2025 disposition of 3,193 shares for the withholding of restricted stock units by the Issuer to satisfy FICA taxes arising from the Reporting Person being retirement eligible which was previously inadvertently not reported; not an open market transaction.

3. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)